Prostate Neoplasms Completed Phase 2 Trials for Abiraterone (DB05812)

Also known as: Neoplasm, Prostate / Neoplasms, Prostate / Prostate Neoplasm

IndicationStatusPhase
DBCOND0031071 (Prostate Neoplasms)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00474383An Safety and Efficacy Study of Abiraterone Acetate in Participants With Advanced Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based ChemotherapyTreatment
NCT00544440An Observational Study of Continuous Oral Dosing of Abiraterone Acetate in Castration-Resistant Prostate Cancer Patients Evaluating Androgens and Steroid Metabolites in Bone Marrow PlasmaTreatment
NCT01424930A Study to Determine the Short-Term Safety of Continuous Dosing of Abiraterone Acetate and Prednisone in Modified Fasting and Fed States to Patients With Metastatic Castration-Resistant Prostate CancerTreatment
NCT01553188AMG 386 and Abiraterone for Advanced Prostate CancerTreatment